228 related articles for article (PubMed ID: 35735794)
1. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
[TBL] [Abstract][Full Text] [Related]
3. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Hepatol Int; 2022 Apr; 16(2):282-293. PubMed ID: 35075593
[TBL] [Abstract][Full Text] [Related]
4. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
Lim YS; Seto WK; Kurosaki M; Fung S; Kao JH; Hou J; Gordon SC; Flaherty JF; Yee LJ; Zhao Y; Agarwal K; Lampertico P
Aliment Pharmacol Ther; 2022 Apr; 55(8):921-943. PubMed ID: 35178711
[TBL] [Abstract][Full Text] [Related]
5. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
Buti M; Marcos-Fosch C; Esteban R
Liver Int; 2021 Jun; 41 Suppl 1():9-14. PubMed ID: 34155802
[TBL] [Abstract][Full Text] [Related]
6. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
[TBL] [Abstract][Full Text] [Related]
8. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir.
Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ
Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480
[TBL] [Abstract][Full Text] [Related]
9. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
Lee IC; Lan KH; Su CW; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232631
[TBL] [Abstract][Full Text] [Related]
11. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
Farag MS; Fung S; Tam E; Doucette K; Wong A; Ramji A; Conway B; Cooper C; Tsoi K; Wong P; Sebastiani G; Brahmania M; Haylock-Jacobs S; Coffin CS; Hansen BE; Janssen HLA
J Viral Hepat; 2021 Jun; 28(6):942-950. PubMed ID: 33749086
[TBL] [Abstract][Full Text] [Related]
13. Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study.
Ogawa E; Jun DW; Toyoda H; Hsu YC; Yoon EL; Ahn SB; Yeh ML; Do S; Trinh HN; Takahashi H; Enomoto M; Kawada N; Yasuda S; Tseng CH; Kawashima K; Lee HA; Inoue K; Haga H; Do AT; Maeda M; Hoang JH; Cheung R; Ueno Y; Eguchi Y; Furusyo N; Yu ML; Tanaka Y; Nguyen MH
Aliment Pharmacol Ther; 2024 Jan; 59(2):239-248. PubMed ID: 37882252
[TBL] [Abstract][Full Text] [Related]
14. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Toyoda H; Leong J; Landis C; Atsukawa M; Watanabe T; Huang DQ; Liu J; Quek SXZ; Ishikawa T; Arai T; Yokohama K; Chuma M; Takaguchi K; Uojima H; Senoo T; Dang H; Maeda M; Hoang J; Le RH; Yasuda S; Thin KN; Tran S; Chien N; Henry L; Asai A; Fukunishi S; Cheung R; Lim SG; Trinh HN; Nguyen MH
Hepatology; 2021 Aug; 74(2):656-666. PubMed ID: 33706421
[TBL] [Abstract][Full Text] [Related]
15. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
[TBL] [Abstract][Full Text] [Related]
16. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Uchida Y; Nakao M; Yamada S; Tsuji S; Uemura H; Kouyama JI; Naiki K; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mochida S
PLoS One; 2022; 17(2):e0262764. PubMed ID: 35180213
[TBL] [Abstract][Full Text] [Related]
17. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
Cheng PN; Feng IC; Chen JJ; Kuo HT; Lee PL; Yu ML; Chiu YC; Chiu HC; Chien SC; Chen PJ; Liu CJ
Aliment Pharmacol Ther; 2024 Jan; 59(2):230-238. PubMed ID: 37845815
[TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
Bernstein DE; Trinh HN; Schiff ER; Smith CI; Mospan AR; Zink RC; Fried MW; Lok AS
Dig Dis Sci; 2022 Jun; 67(6):2637-2645. PubMed ID: 34059991
[TBL] [Abstract][Full Text] [Related]
19. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia.
Charlton MR; Alam A; Shukla A; Dashtseren B; Lesmana CRA; Duger D; Payawal DA; Duy Cuong D; Jargalsaikhan G; Cua IHY; Sollano JD; Singh KR; Madan K; Win KM; Kyi KP; Tun KS; Salih M; Rastogi M; Saraf N; Thuy PTT; Hien PTD; Gani RA; Mohamed R; Tanwandee T; Piratvisuth T; Sukeepaisarnjaroen W; Naing W; Hashmi ZY
J Gastroenterol; 2020 Sep; 55(9):811-823. PubMed ID: 32666200
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
